THE RENOPROTECTIVE EFFECT OF SODIUM-GLUCOSE COTRANSPORTER2 (SGLT2) INHIBITOR DAPAGLIFLOZIN IN TYPE 1 DIABETES

被引：0
|
作者：
Hodrea, Judit [1 ]
Lenart, Lilla [1 ]
Koszegi, Sandor [1 ]
Gellai, Renata [1 ]
Balogh, Dora B. [1 ]
Vannay, Adam [2 ]
Wagner, Laszlo J. [3 ]
Szabo, Attila J. [4 ]
Fekete, Andrea [1 ]
机构：
[1] Mta Se LendUlet Diabet Res Grp, Budapest, Hungary
[2] Mta Se Pediat & Nephrol Res Grp, Budapest, Hungary
[3] Semmelweis Univ, Dept Transplanat & Surg, H-1085 Budapest, Hungary
[4] Semmelweis Univ, Dept Pediat 1, H-1085 Budapest, Hungary
来源：
PEDIATRIC NEPHROLOGY | 2015年 / 30卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
P - 216
引用
收藏
页码：1633 / 1634
页数：2
相关论文
共 50 条
  • [21] DAPAGLIFLOZIN, AN SGLT2 INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES
    Demaris, K. M.
    White, J. R.
    DRUGS OF TODAY, 2013, 49 (05) : 289 - 301
  • [22] Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Type 1 Diabetes: A Systematic Review and Meta-analysis
    El Masri, Dana
    Jaber, Linda
    DIABETES, 2017, 66 : LB41 - LB41
  • [23] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes
    Xin Liao
    Xuemei Wang
    Haopeng Li
    Ling Li
    Guohao Zhang
    Mengliu Yang
    Lei Yuan
    Hua Liu
    Gangyi Yang
    Lin Gao
    Scientific Reports, 6
  • [24] Dapagliflozin, an SGLT2 inhibitor, for diabetes
    Hanefeld, Markolf
    Forst, Thomas
    LANCET, 2010, 375 (9733): : 2196 - 2198
  • [25] Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Tune 2 Diabetes
    Choi, Jin Bong
    Yoo, Je Mo
    Lee, Ye-Jee
    Kim, Jae Woong
    Lee, Seung-Ju
    Kim, Hee Youn
    Lee, Dong Sup
    Ko, Seung-Hyun
    Choe, Hyun-Sop
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2020, 24 (01) : 21 - 28
  • [26] Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
    Derosa, Giuseppe
    Maffioli, Pamela
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1637 - 1640
  • [27] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
    Jasleen, Bains
    Vishal, Gupta K.
    Sameera, Malepati
    Fahad, Molla
    Brendan, O'Brien
    Deion, Santander
    Pemminati, Sudhakar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [28] Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glycosuria to the treatment of type 2 diabetes mellitus
    Perez Lopez, G.
    Gonzalez Albarran, O.
    Cano Megias, M.
    NEFROLOGIA, 2010, 30 (06): : 618 - 625
  • [29] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
    Andreea, Munteanu Madalina
    Surabhi, Swarnkar
    Razvan-Ionut, Popescu
    Lucia, Ciobotaru
    Camelia, Nicolae
    Emil, Tufanoiu
    Tiberiu, Nanea Ioan
    MEDICINA-LITHUANIA, 2023, 59 (04):
  • [30] Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis
    Dholariya, Sagar
    Dutta, Siddhartha
    Singh, Ragini
    Parchwani, Deepak
    Sonagra, Amit
    Kaliya, Mehul
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (18) : 2187 - 2198
12345